Form 4: IRADIMED CEO Sells 5,000 Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, Roger E. Susi, sold 5,000 shares of common stock in pre-planned transactions on November 18, 2025.

Summary

• Roger E. Susi, who serves as CEO, President, Chairman, Director, and 10% Owner of IRADIMED CORP (IRMD), reported the sale of 5,000 shares of common stock.
• The sales occurred on November 18, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
• The transactions involved two separate sales from the Phillip Susi 2008 Dynasty Trust.
• The first sale was for 3,184 shares at a weighted average price of $85.29, with individual trade prices ranging from $84.80 to $85.78.
• The second sale was for 1,816 shares at a weighted average price of $86.12, with individual trade prices ranging from $85.79 to $86.38.
• Following these transactions, Roger E. Susi's indirect beneficial ownership includes 2,312,500 shares via the Phillip Susi 2008 Dynasty Trust, 162,950 shares via the Roger E. Susi Revocable Trust, and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust (for which beneficial ownership is disclaimed except to the extent of his pecuniary interest).

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to an insider sale, but significantly mitigated by the fact it was conducted under a pre-planned 10b5-1 trading plan, which reduces the implication of a lack of confidence in the company's immediate future. The amount sold represents a very small fraction of the insider's total beneficial ownership.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating they were not based on new, non-public information and were part of a scheduled financial management strategy.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

This is an insider transaction report and does not directly relate to broader industry trends or competitor performance. Its primary impact is on the perception of IRADIMED's stock and the insider's stake.

Related Party Transactions

• The sales were made from the Phillip Susi 2008 Dynasty Trust, an entity indirectly beneficially owned by Roger E. Susi, making it a related party transaction.

Stakeholder Impact

• Shareholders might perceive the insider sale as a slight negative, though the 10b5-1 plan mitigates concerns about immediate company prospects.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Recommendation

While an insider sale can sometimes signal a lack of confidence, the fact that these transactions were executed under a pre-arranged Rule 10b5-1 plan suggests they are part of the insider's personal financial management rather than a reaction to new, adverse company developments. Given the relatively small percentage of total beneficial ownership sold (approximately 0.11% of over 4.5 million indirectly held shares), and without additional context on company performance or market conditions, a 'hold' recommendation is appropriate. Investors should monitor future filings and company performance for more definitive signals.

Keywords

IRADIMED CORP, IRMD, Roger E. Susi, Insider Sale, Form 4, SEC Filing, Stock Transaction, 10b5-1 Plan, CEO, Director, 10% Owner